Lyell Immunopharma reports Q3 net loss $44.6M; cash $460.7M funds into 2027

Lyell Immunopharma, Inc.

2024-Q3 EPS reported -$0.59 revenue$50,000

Net loss of $44.6M for Q3 2024, improved from $50.9M in Q3 2023; non-GAAP net loss $37.1M.
Cash, cash equivalents and marketable securities $460.7M as of Sept 30, 2024; provides runway into 2027.
Completed ImmPACT Bio acquisition; added IMPT-314, a CD19/CD20 CAR T candidate with Phase 1 data at ASH 2024.
Expect to initiate pivotal trial for IMPT-314 in 2025 in relapsed/refractory LBCL; initial Phase 1 data at ASH Dec 9.
Phase 1 trial of LYL119 for ROR1-positive solid tumors ongoing; initial clinical data expected H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.